Effects of ozone treatment to the levels of neurodegeneration biomarkers after rotenone induced rat model of Parkinson's disease

Basit Öğe Kaydı
dc.authorscopusid58538502100
dc.authorscopusid57202645325
dc.authorscopusid58538340000
dc.authorscopusid58538983000
dc.authorscopusid58538502200
dc.authorscopusid56197950800
dc.authorscopusid6506580350
dc.contributor.authorKaplan, Algin, A.
dc.contributor.authorTomruk, C.
dc.contributor.authorGözde, Aslan, Ç.
dc.contributor.authorSaban, Akkurt, S.
dc.contributor.authorMehtap, Çinar, G.
dc.contributor.authorUlukaya, S.
dc.contributor.authorUyanıkgil, Y.
dc.date.accessioned2024-08-25T18:35:54Z
dc.date.available2024-08-25T18:35:54Z
dc.date.issued2023
dc.departmentEge Üniversitesien_US
dc.description.abstractThe study investigated the effects of ozone treatment on the neurodegeneration of stereotaxic rotenone-induced parkinson's disease (PD) model. The model was confirmed using the apomorphine rotation test. ?-synuclein, amyloid-?, Tau, phosphorylated Tau, as well as tyrosine hydroxylase(+), nNOS(+), and glial cell counts were used to evaluate neurodegeneration in the substantia nigra pars compacta and ventral tegmental area. The experiment involved 48 Sprague-Dawley rats divided into four groups: dimethyl sulfoxide (DMSO), DMSO with ozone (O), DMSO/rotenone (R), and D/R/O. Ozone treatment significantly improved tissue ?-synuclein level and TH+, nNOS+, and glial cell counts compared to the rotenone-only group. The study suggests that ozone treatment may have beneficial effects on PD biomarkers in the rotenone model. Further studies on ozone dosage, duration, and administration methods in humans could provide more evidence for its potential use in Parkinson's disease treatment. © 2023 Elsevier B.V.en_US
dc.description.sponsorshipTGA-2019-20564en_US
dc.description.sponsorshipAuthors are thankful by support of Ege University Scientific Research Projects Coordination (TGA-2019-20564).en_US
dc.identifier.doi10.1016/j.neulet.2023.137448
dc.identifier.issn0304-3940
dc.identifier.pmid37597740en_US
dc.identifier.scopus2-s2.0-85168093644en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1016/j.neulet.2023.137448
dc.identifier.urihttps://hdl.handle.net/11454/100464
dc.identifier.volume814en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Ireland Ltden_US
dc.relation.ispartofNeuroscience Lettersen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240825_Gen_US
dc.subjectNeurodegenerative diseaseen_US
dc.subjectOzoneen_US
dc.subjectParkinson's diseaseen_US
dc.subjectRotenoneen_US
dc.subjectalpha synucleinen_US
dc.subjectamyloid beta proteinen_US
dc.subjectamyloid beta protein[1-42]en_US
dc.subjectbiological markeren_US
dc.subjectdimethyl sulfoxideen_US
dc.subjectketamineen_US
dc.subjectozoneen_US
dc.subjectrotenoneen_US
dc.subjecttau proteinen_US
dc.subjecttyrosineen_US
dc.subjectxylazineen_US
dc.subjectanimal cellen_US
dc.subjectanimal experimenten_US
dc.subjectanimal modelen_US
dc.subjectapomorphine testen_US
dc.subjectArticleen_US
dc.subjectbiochemistryen_US
dc.subjectcell counten_US
dc.subjectcontrolled studyen_US
dc.subjectgene expressionen_US
dc.subjectglia cellen_US
dc.subjectimmunohistochemistryen_US
dc.subjectmaleen_US
dc.subjectnerve degenerationen_US
dc.subjectnonhumanen_US
dc.subjectParkinson diseaseen_US
dc.subjectprotein phosphorylationen_US
dc.subjectraten_US
dc.subjectSprague Dawley raten_US
dc.subjectstereotactic treatmenten_US
dc.subjectsubstantia nigra pars compactaen_US
dc.subjectventral tegmentumen_US
dc.titleEffects of ozone treatment to the levels of neurodegeneration biomarkers after rotenone induced rat model of Parkinson's diseaseen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu